Literature DB >> 19952874

Adjunctive low-dose amisulpride in motor conversion disorder.

Panagiotis Oulis1, Nikolaos Kokras, George N Papadimitriou, Vasilios G Masdrakis.   

Abstract

Extant pharmacological options for motor conversion disorder include mainly antidepressants and benzodiazepines. We report on the case of a 42-year-old female patient with frequent daily episodes of almost complete paralysis for the last 6 months resistant to an escitalopram-lorazepam combination at adequate doses. By contrast, the adjunctive administration of low-dose amisulpride at 200 mg/d to the patient's regimen resulted in her substantial and durable improvement. We hypothesize that low-dose amisulpride, acting as a selective antagonist of D2 and D3 dopamine autoreceptors, might reverse the decreased activity of frontal and subcortical dopaminergic circuits presumably involved in motor control during hysterical paralysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952874     DOI: 10.1097/WNF.0b013e3181b20144

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Hysterical paralysis after spinal surgery.

Authors:  Liang Zhu; Bin Ni; Qunfeng Guo
Journal:  Rheumatol Int       Date:  2011-11-10       Impact factor: 2.631

2.  First episode of psychosis in a middle-aged patient with a 14-year history of conversion disorder.

Authors:  Vaios Peritogiannis; Thiresia Manthopoulou; Venetsanos Mavreas
Journal:  Case Rep Psychiatry       Date:  2014-12-18

Review 3.  Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review.

Authors:  Vasilios G Masdrakis; David S Baldwin
Journal:  Ther Adv Psychopharmacol       Date:  2021-03-21

4.  [Postoperative visual loss due to conversion disorder after spine surgery: a case report].

Authors:  Dailson Mamede Bezerra; Eglantine Mamede Bezerra; Antonio Jorge Silva Junior; Marco Aurélio Soares Amorim; Denismar Borges de Miranda
Journal:  Braz J Anesthesiol       Date:  2016-01-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.